Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AqT-Calicheamicin
- Development stage
- Preclinical
- Lead developer
- AqueaTether Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
AqT-Calicheamicin is a specialized antibody-drug conjugate (ADC) payload developed by AqueaTether Therapeutics, a subsidiary or partner of CellMosaic. It consists of the potent cytotoxic agent calicheamicin modified with AqueaTether (AqT) technology, which utilizes a highly hydrophilic, non-immunogenic polymer to improve the solubility and conjugation properties of the payload. Calicheamicin is a small molecule enediyne antibiotic that binds to the minor groove of DNA and undergoes a Bergman cyclization to generate a diradical, leading to site-specific double-strand DNA cleavage and subsequent cell death. The AqT-Calicheamicin asset is primarily used as a platform tool for the development of novel ADCs targeting various cancers, aiming to overcome the hydrophobicity and aggregation issues often associated with traditional calicheamicin-based conjugates.
- Other names
- CalicheamicinAqueaTether-Calicheamicin
02
Targets
DNA
Beyond the preview
Go deeper on AqT-Calicheamicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AqT-Calicheamicin.